Potential to Differentiate into Spinal Disc
fwiw...Just parking for future reference.
biz.yahoo.com
Best of luck,
SS
>>>>
Cytori Therapeutics Demonstrates Human Adipose-Derived Adult Stem Cells Have the Potential to Differentiate into Spinal Disc
Wednesday September 28, 2:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Sept. 28, 2005--Cytori Therapeutics, Inc. (Frankfurt: XMP - News), today announced research results illustrating that human adipose-derived adult stem cells can differentiate into cells displaying the phenotype of nucleus pulposus (NP) cells. The nucleus pulposus, which forms the soft gel-like center of an intervertebral disc, is adversely affected in degenerative disc disease. These data were presented (Abstract #: P116) at the 20th annual North American Spine Society conference September 27 - October 1, 2005 in Philadelphia, Pennsylvania.
"Our research demonstrates the potential for using human adipose-derived stem cells in treating patients with degenerative disc disease," stated Christopher J. Calhoun, Chief Executive Officer for Cytori Therapeutics. "We are encouraged by these early findings and have initiated preclinical animal studies to further evaluate the effect of these cells, in vivo, on injured discs."
In a poster presentation at the Conference, scientists from the Skeletal Tissue Engineering Group Amsterdam (STEGA) and Cytori Therapeutics demonstrated that an NP-phenotype was observed when adipose stem cells were grown in conditions that can be adapted to clinical practice. The human adipose stem cells and NP cells were co-cultured for 14 days. RNA expression analysis found the presence of genes which are markers of mature NP cells. One of the genes in particular forms a protein that is critical to the function of the nucleus pulposus.
About Cytori Therapeutics
Cytori Therapeutics (Frankfurt: XMP - News) is discovering and developing proprietary cell-based therapeutics utilizing adult stem cells derived from adipose, also known as fat tissue. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem cells, Cytori is developing its proprietary Celution(TM) system to isolate and concentrate a patient's own stem cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events and trends which may affect Cytori Therapeutics' future operating results and financial position. Such statements are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially. Some of these risks and uncertainties are described (under the heading "Risk Factors") in Cytori Therapeutics' 2004 Form 10-K annual report for the year ended December 31, 2004 and subsequent SEC filings, which are available through the Company's web site. Cytori Therapeutics assumes no responsibility to update any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made.
--------------------------------------------------------------------------------
Contact:
Cytori Therapeutics, Inc.
Media/U.S. Investors:
Tom Baker, +1-858-458-0900
tbaker@cytoritx.com
OR
International Investors:
Stefanie Bacher, +1-858-458-0900
sbacher@cytoritx.com
--------------------------------------------------------------------------------
Source: Cytori Therapeutics, Inc. |
